FeaturedProfiles.com Free Stock Pick: Maxygen (MAXY)

July 2nd, 2008

FeaturedProfiles.com Stock Pick: Maxygen, Inc. (MAXY)

Stock Price: $4.48

Maxygen, Inc. is a biotechnology company that engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions in the United States.

MAXY was a huge gainer today, up $0.97 to $4.48, but we don't believe it has yet seen the serious money it deserves from investors. The company announced that Bayer will pay up to $120 million for Maxygen's hemophilia program.

MAXY will receive a $90 million payment up front. Bayer is very high on MAXY's next-generation recombinant Factor VIIa protein for treatment of hemophilia patients.

MAXY may have lost a major asset, but they received a huge chunk of cash that they can use to further their other drug candidates and do further research & development.

MAXY is now trading at a market cap of only around $165.96 million. As of the company's latest quarter, there was $133.58 million in cash, cash equivalents and short-term investments on the balance sheet. Now, add $90 million to this cash balance and you have over $223 million in cash, cash equivalents and short-term investments.

Also, consider MAXY has no debt on their balance sheet and only $10.22 million in total liabilities. The company has also proven that they can sell a drug candidate even before FDA trials for a huge amount of cash. MAXY has a ton of momentum right now, internally and with their stock.

We believe we could see MAXY trading at much higher levels once more investors research it.








			July 2nd, 2008 FeaturedProfiles.com Stock Pick: Maxygen, Inc. (MAXY) Stock Price: $4.48 Maxygen, Inc. is a biotechnology company that engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions in the United States. MAXY was a huge gainer today, up $0.97 to $4.48, but we don't believe it has yet seen the serious money it deserves from investors. The company announced that Bayer will pay up to $120 million for Maxygen's hemophilia program. MAXY will receive a $90 million payment up front. Bayer is very high on MAXY's next-generation recombinant Factor VIIa protein for treatment of hemophilia patients. MAXY may have lost a major asset, but they received a huge chunk of cash that they can use to further their other drug candidates and do further research & development. MAXY is now trading at a market cap of only around $165.96 million. As of the company's latest quarter, there was $133.58 million in cash, cash equivalents and short-term investments on the balance sheet. Now, add $90 million to this cash balance and you have over $223 million in cash, cash equivalents and short-term investments. Also, consider MAXY has no debt on their balance sheet and only $10.22 million in total liabilities. The company has also proven that they can sell a drug candidate even before FDA trials for a huge amount of cash. MAXY has a ton of momentum right now, internally and with their stock. We believe we could see MAXY trading at much higher levels once more investors research it.
			DISCLAIMER & RISK DISCLOSURE: FeaturedProfiles.com and SpeculatingStocks.com, Inc. and our affiliates ("our companies") are not registered investment advisers or broker/dealers. Our companies make no commitment that the purchase of securities of companies profiled or otherwise mentioned in our websites are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the possible lack of liquidity for their securities, investing in such securities is highly speculative and carries a high degree of risk. Never invest based solely on information from this Web site or our email alerts. Our FeaturedProfiles.com Newsletter is our free alert email membership. We profile selected companies on our site. These companies compensate SpeculatingStocks.com, Inc. for profile coverage. This compensation can be found in the disclosure on the bottom of the page of profiles. This Disclaimer & Risk Disclosure is also at the bottom of profiles. Specific questions on membership or profiles can be obtained by writing the FeaturedProfiles.com at: staff@featuredprofiles.com.